Senate committee hears hours of testimony on clinician‑led psilocybin program bill

The Washington Senate Health and Long Term Care Committee on Jan. 27 heard hours of public testimony on Senate Bill 5921, a proposal to create a clinician‑led, Department of Health‑regulated medical psilocybin program.

Committee staff Jacob Ewing summarized the bill as establishing two license types — a producer license and a clinician participation license — and delegating to DOH the authority to set training, treatment and dosage standards, data‑collection requirements, and criminal‑history background checks via the Washington State Patrol and the FBI. The bill specifies that qualifying‑condition determinations would be made by the prescribing clinician and that the program would take effect on July 1, 2028.

Senator Jesse Solomon (32nd District), the prime sponsor, told the committee the bill follows a clinician‑controlled model similar to New Mexico’s law and described psilocybin as a medicine with potential to produce rapid, durable improvements for some people with treatment‑resistant depression and PTSD. He cited a $2 million clinical trial currently enrolling veterans and first responders that the sponsor said would yield additional data in 2026.

Proponents included clinicians and people with lived experience who described substantial benefits after supervised access. Matt Therfelder, a retired battalion chief, said supervised psilocybin accessed under Oregon’s Measure 109 “dramatically improved my life.” Psychiatrists and researchers testifying — including Dr. Edward Cates and Robert Kaufman, a retired Navy psychiatrist — emphasized clinical trial evidence that psilocybin delivered with screening, preparation, monitoring and integration sessions has shown sustained remission in some patients.

Clinicians and trial staff described typical course elements for psilocybin‑assisted psychotherapy: screening and medical/psychiatric history, 2–3 preparatory sessions, a six‑ to eight‑hour dosing day with monitoring, and post‑dosing integration sessions.

Opponents and cautious voices raised clinical‑safety and access concerns. Amy Brackenberry, testifying for the Washington State Medical Association, said SB 5921 lacks required screening for contraindications, explicit medical monitoring during dosing sessions, rescue medications, and a required second person on site or equivalent monitoring. Multiple witnesses warned the bill could impose pharmaceutical‑grade manufacturing and testing standards on naturally derived psilocybin, increasing costs and leaving access limited to higher‑income patients.

Several witnesses representing advocacy organizations and facilitator networks urged the committee to include personal and community‑use protections or broaden workforce permissions beyond physicians, arguing that a strictly medicalized system could create a two‑tier system that criminalizes nonmedical community models while privileging an expensive clinical pathway.

Testimony reflected a split in the community: veterans and clinicians urged regulated access as a safer alternative to unregulated care, while some advocates and medical organizations pressed for stronger procedural safeguards, clearer workforce and integration requirements, and attention to affordability and local decision‑making. Chair Cleveland closed the hearing after noting numerous people had signed in to testify.